Aug 20 — Yingxi Intelligence said it has signed a formal R&D collaboration with
Byterna Therapeutics to build a next‑generation, AI‑native mRNA R&D engine. The
partnership will focus on AI neoantigen prediction and sequence design, circular
mRNA, targeted delivery, automated experimentation and smart manufacturing to
develop personalized cancer vaccines and related therapies.